BETA: Please send your feedback!
Intercept Pharmaceuticals
ICPT:NAS
Pharmaceuticals: Other
$2.22bn
SMALL cap
$67.79
(2.72%)
-0.29%
since start of 2019
-6.48
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Pharmaceuticals: Other
Founded 2002
Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
website
Headquarters
Executives
| Name | Title | Gender |
| David A. Shapiro, MD | Chief Medical Officer & Executive VP-Development | Male |
| Mark E. Pruzanski, MD | President, Chief Executive Officer & Director | Male |
| Paolo Fundar | Chairman | Male |
| Roberto Pellicciari, PhD | Founder | Male |
| Mark J. Vignola, PhD | Director-Investor Relations | Male |
| Sandip S. Kapadia, MBA, CPA | Chief Financial Officer | Male |
| Jerome B. Durso | Chief Operating Officer | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Intercept Pharmaceuticals - Competitors and Related Companies
How Intercept Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Intercept Pharmaceuticals
ICPT:NAS
Pharmaceuticals: Other
$2.22bn
SMALL cap
$67.79
(2.72%)
-0.29%
since start of 2019
-6.48
MediciNova
MNOV:NAS
Biotechnology
$354.01mm
SMALL cap
$8.16
(0.35%)
-0.00%
since start of 2019
-22.33
Conatus Pharmaceuticals
CNAT:NAS
Biotechnology
$12.02mm
MICRO cap
$0.36
(-0.01%)
-0.83%
since start of 2019
-0.82
Enzon Pharmaceuticals
ENZN:NAS
Biotechnology
$0
MICRO cap
$0.22
(-0.01%)
-0.09%
since start of 2019
1.63
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
$87.02bn
MEGA cap
$53.20
(0.17%)
0.01%
since start of 2019
13.96
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
$104.18bn
MEGA cap
$107.91
(-0.73%)
-0.06%
since start of 2019
25.65